A higher risk of adult psychotic experiences is associated with childhood cat ownership.

Published Date: 24 Apr 2023

Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.

Read Full News

Latest News

Q3 2026 Recap: Psychiatry News and Updates

5 Psychiatry Headlines You Missed in September 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know Andrew Leuchter, MD, Scott A. Wilke, MD, PhD, Linda Carpenter, MD

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD John Sonnenberg, PhD

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Q2 2026 Recap: Psychiatry News & Updates Chelsie Derman

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Latest News

Q3 2026 Recap: Psychiatry News and Updates

5 Psychiatry Headlines You Missed in September 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

News All Time

FDA Approves Centanafadine for ADHD in Adults, Children Aged ≥ 6 Years Chelsie Derman

The first-in-class NDSRI showed significant symptom improvement as early as week 1 across 4 phase 3 trials but carries boxed warnings for suicidality and abuse potential.

Ketamine, Psychedelics Share Neuroimmune Signature in TRD Chelsie Derman

A biomarker study links immune signaling (IL-7/IL-15) and brain gamma-wave activity to ketamine response in TRD.

Metabolic Traits Differentiate AERS+, AERS− MDD Subtypes, With Arvid Harder Arvid Harder

New genome-wide data show AERS+ and AERS− subtypes of major depressive disorder diverge in heritability and metabolic genetic correlations.

Voyage: DT120 ODT Reduces Anxiety in Phase 3 GAD Trial Chelsie Derman

DT120 ODT produced a 5.4-point placebo-adjusted HAM-A reduction at week 12 in the phase 3 Voyage trial for generalized anxiety disorder.

AERS Subtypes Show Distinct Genetic Architecture in MDD Arvid Harder

A genome-wide study of > 460,000 individuals identify 27 loci separating AERS+ and AERS− subtypes of major depressive disorder by metabolic profile.

MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD Chelsie Derman

Resilient Pharmaceuticals has resubmitted its MDMA-assisted therapy NDA for PTSD without a new phase 3 trial, MAPS reported.

TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD Jonathan Downar, MD, PhD

Downar says shorter sessions, accelerated schedules, and expanding neuroimaging maps have made TMS effective for more patients in far fewer visits.

Lower TMS Intensity Correlates With Greater Depression Improvement Chelsie Derman

A randomized TMS trial found lower DLPFC electric-field strength, not higher intensity, correlated with greater depression improvement.

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD Chelsie Derman

The FDA granted DT120 (lysergide) ODT Breakthrough Therapy designation for MDD, citing promising phase 3 Emerge data.

Do More TMS Pulses Track with Better Depression Outcomes? Jonathan Downar, MD, PhD

A new meta-analysis found total pulse count predicted outcomes in a roughly linear pattern across sham-controlled trials of accelerated rTMS.

Q&A: Accelerated TMS Speeds Suicidal Ideation Relief, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

SWIFT accelerated Deep TMS resolved suicidal ideation faster than standard dosing, Owen Muir, MD, says.

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

Walmart Pasta Recall; 'Ketamine Bladder' in Kids; Panettiere's Cause of Death

Health news and commentary gathered by MedPage Today staff

Safety Concerns Halt Depression Trials; Gen Z and Alcohol; Prescribing Benzos

— News and commentary from the psychiatry world

In 18 States, alcohol exclusion laws are still in effect.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

Prostate cancer detection with PET CT and PET MRI is comparable.

3.

Healthcare AI, Meant to Save Money, Turns Out to Require a Lot of Expensive Humans

4.

Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT

5.

EHA: European Hematology Association

1.

Tumor Microenvironment Mapping in Cancer Care

2.

Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained

3.

Preventing Treatment-Induced Peripheral Neuropathy in Cancer Care

4.

Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology

5.

Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Understanding Blood Clotting Disorders

2.

Thromboprophylaxis In Medical Settings

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

5.

Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

A higher risk of adult psychotic experiences is associated with childhood cat ownership.

Latest News

Q3 2026 Recap: Psychiatry News and Updates

5 Psychiatry Headlines You Missed in September 2026

What The FDA Psychedelic Hearing Means for Psychiatrists

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know Andrew Leuchter, MD, Scott A. Wilke, MD, PhD, Linda Carpenter, MD

Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD John Sonnenberg, PhD

Q2 2026 Recap: Psychiatry News & Updates Chelsie Derman

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Latest News

News All Time

FDA Approves Centanafadine for ADHD in Adults, Children Aged ≥ 6 Years Chelsie Derman

Ketamine, Psychedelics Share Neuroimmune Signature in TRD Chelsie Derman

Metabolic Traits Differentiate AERS+, AERS− MDD Subtypes, With Arvid Harder Arvid Harder

Voyage: DT120 ODT Reduces Anxiety in Phase 3 GAD Trial Chelsie Derman

AERS Subtypes Show Distinct Genetic Architecture in MDD Arvid Harder

MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD Chelsie Derman

TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD Jonathan Downar, MD, PhD

Lower TMS Intensity Correlates With Greater Depression Improvement Chelsie Derman

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD Chelsie Derman

Do More TMS Pulses Track with Better Depression Outcomes? Jonathan Downar, MD, PhD

Q&A: Accelerated TMS Speeds Suicidal Ideation Relief, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use

Walmart Pasta Recall; 'Ketamine Bladder' in Kids; Panettiere's Cause of Death

Safety Concerns Halt Depression Trials; Gen Z and Alcohol; Prescribing Benzos

Recommended News For You

Patients With Early-Onset Cancer Unaware of Infertility Risk

Big Gain in PFS With Metastasis-Directed RT for Oligometastatic Pancreatic Cancer

A large study found that monolayers were superior in detecting cancer.

Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy

In 18 States, alcohol exclusion laws are still in effect.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

Recommended Articles For You

The Latest Research on Wiskott Aldrich Syndrome

Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth

Understanding Lymphedema: Symptoms, Causes, and Treatment

Survival Rates in Cancer: Focus on Acute Myeloid Leukemia and Other Malignancies

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.